The group believes its assay, which detects HPV-16 DNA, could be deployed as a screening test in the way that HPV is currently screened to prevent cervical cancer.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
The genomics firm is expecting major revenue decreases in every geographic region but sees signs of hope that business can pick up again later in the year.
The platform's portability and internet connectivity could enable it to locate and track the distribution of disease in real time, its developers said.
The immune sequencing firm has engaged the FDA in discussions over how to get regulatory approval for one test for several seemingly different diseases.
Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.
